Novo Nordisk shares slip on cautious guidance, insulin pricing concerns

Shares in Novo Nordisk (NYSE:NVO) fell slightly today after the insulin-maker met expectations on Wall Street with its third quarter results, but issued cautious sales guidance for 2018.

The company’s chief executive expressed concerns that draft legislation to make drug pricing more transparent could potentially hurt the industry, according to Reuters.

Get the full story at our sister site, Drug Delivery Business News.

The post Novo Nordisk shares slip on cautious guidance, insulin pricing concerns appeared first on MassDevice.

from MassDevice http://ift.tt/2A7zThR